Understanding Viscosupplementation for Knee Osteoarthritis
Educational overview - not medical advice.
Osteoarthritis (OA) is a degenerative joint condition in which the cartilage cushioning a joint gradually breaks down, and the synovial fluid that normally lubricates the joint loses some of its natural viscosity and elasticity. In the knee, this typically presents as pain, stiffness and reduced mobility that worsens with activity.
What is viscosupplementation?
Viscosupplementation is the injection of hyaluronic acid (HA) - a naturally occurring component of healthy synovial fluid - directly into the joint space. The goal is to supplement the joint's own lubricating fluid, which is often thinner and less effective in an osteoarthritic joint, helping to cushion the joint and support smoother movement.
Modern formulations use cross-linked hyaluronic acid, where HA molecules are chemically bonded into a more stable network. This slows the natural breakdown of HA in the joint, allowing a single injection to remain effective for months rather than days.
Where it fits in osteoarthritis care
Clinical guidance generally positions viscosupplementation as an option for patients with mild-to-moderate osteoarthritis who have not had adequate relief from first-line measures such as weight management, physiotherapy, or oral pain relief - particularly patients who cannot tolerate NSAIDs long-term, or who experience side effects from them. It is not a cure for osteoarthritis and does not reverse existing cartilage damage; rather, it aims to manage symptoms and may help delay the need for more invasive interventions.
What the evidence shows
A post-marketing phase IV study of a single-injection, cross-linked hyaluronic acid treatment for knee osteoarthritis (Bashaireh et al., 2015, Drug Design, Development and Therapy) followed patients over 12 months and reported significant reductions in pain and stiffness scores, with improvement apparent from the first month and peaking around month five. Findings like these support single-injection HA products as a practical option that reduces the number of clinic visits compared with older multi-injection courses, which can also lower cumulative infection risk and improve patient adherence.
What to discuss with a doctor
- Whether your osteoarthritis stage and symptoms make you a suitable candidate.
- Any known allergies or sensitivities, including to local anesthetics if a combination product is used.
- Realistic expectations for onset, duration and degree of symptom relief.
Source: Bashaireh, K., Sorour, S., Al Hawadya, K., Naser, Z. and Al-khateeb, R. (2015). Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing phase IV study. Drug Design, Development and Therapy, 9:2063-2072.
See Crespine Gel product details → · See Crespine Gel Plus product details →